Assessment of markers of systemic inflammation, such as acute-phase reactants C-reactive protein (CRP), üb-rinogeti and ceruloplasmin, sialic acid, a major component of these proteins and neopterin, a specific marker of cellular immune activation, in clinically stable coronary artery disease, may contribute to Staging and risk stratification. These markers were measured in 225 consecutive stable coronary artery disease patients before undergoing coronary angiography. According to their angiographic scores 32 patients were designated as having minor, 34 moderate and 96 severe coronary artery disease. 63 patients with negative angiograms were taken as the angiographic controls. High sensitive-CRP (hs-CRP) and fibrinogen were found to be higher in palient.s with angiographically establishcd coronary artery disease, than in angiographic controls (p<0.05) and correlatcd with the scvcrity and extent of disease. Ceruloplasmin and sialic acid concentrations did not differ between patients with and wilhout angiographically cstablished coronary artery disease. Serum neopterin levels were sigificantly higher in patients undergoing coronary angiography than in healthy controls. Neopterin levels were similar between the differcnt subgroups of coronary artery disease, suggestmg that neopterin determinations do not contribute to the assessment of the presence and severity of disease in clinically stable patients. In stable angina, serum hs-CRP and plasma fibrinogen levels proved to be more effective ihan ceruloplasmin, sialic acid and neopterin in discriminating between patients with positive and negative angiograms and various degrees of coronary artery disease, thus in pointing out to increased risk. Our results, do not support the inclusion of neopterin in risk assessment of stable coronary artery disease.
Introduction
high sensitivity C-reactive protein (CRP), fibrinogen, sialic acid (SA), homocysteine, endothelial dysfuncClassical or "traditional" risk factors for coronary tion, oxidative stress and neopterin have been proartery disease (CAD), including elevated serum total posed as new risk factors for the development and proand LDL-cholesterol, low levels of HDL-cholesterol, gression of atherosclerosis and atherothrombotic carhypertension, diabetes mellitus, cigarette smoking and diovascular disease (1) (2) (3) (4) (5) (6) (7) . Accumulation and oxidation advancing age, introduced initially by the Framingham of cholesCerol-rich lipoproteins m the arterial wall Heart Study more than 50 years ago, still serve as the which is followed by an Infiltration of monocytes/ "gold Standard " for coronary risk assessment but do macrophages and T-Iymphocytes, Icads to an inflamnot fully explain the occurrence of atherothromboüc matory response, a key event that leads to the formadisease. More recently, novel serum markers such as tion of atheromatous plaques, ultimately resulting in Gülmen B. al al. : Neopterin and Acute Phase Proteins in Heart Disease CAD. Severa! factors are currently under investigation as inflammatory risk factors or markers of atherosclerosis, including the acute-phase proteins CRP, fibrinogen and ceruloplasmin, SA, a major component of acute phase proteins and neopterin, a raarker of monocyte/macrophage activation. Levels of CRP>03 mg/dl, still within the reference ränge, have been reported to predict acute coronary Syndromes (8) . In addition to acute coronary events, significant elevations in CRP are also reported in Stahle coronary atheroscleosis in the absence of activation (9) . CRP is an acute phase reactant synthesized by the liver upon Stimulation with cytokines, primarily interleukin-6 released from inflamed tissues. Among the possible mechanisms of action for the direct involvement of CRP in atherothrombosis, are complement activation and Stimulation of tissue factor production by monocytes (10) . Since preventive strategies such as aspirin or statin treatment are reported to modify increased coronary risk associated with elevated CRP, it is becoming more and more important to identify with high sensitivity assays, individuals at risk, who would potentially benefit from such treatments. The hemostatic system plays an important role in the pathogenesis of atherosclerosis. Fibrinogen, a key coagulation factor and acute phase reactant exclusiveiy synthesized by the liver is the substrate of the enzyme thrombin and the precursor to fibrin. Fibrinogen plays a central role in thrombosis and hemostasis. It can directly penetrate through the artery wall where it is converted to fibrinogen and promote smooth muscie cell proliferation and migration (11) . Severa! studies have demonstrated significant associations between fibrinogen levels and CAD (12) (13) (14) and other classical risk factors, such as LDL-cholesteroi, blood pressure, age, Smoking andphysical activity (10) . Recent studies have focused on the relation between fibrinogen and other novel inflammatory markers such as CRP, serum amyloid A protein (SAA), interleukin-6 (IL-6) and neopterin (15) .
Ceruloplasmin has been another acute phase protein of interest in atherosclerotic patients. Being a potent catalyst of LDL oxidation in vitro, it is considered a Potential risk factor for predicting myocardial infarction and cardiovascular disease (16) . On the other hand, in human plasma a large amount of SA is found in ceruloplasmin, fibrinogen and other acute phase reactants which are sialylated glycoproteins (17) .
Serum total SA concentrations are reported as being equally strong predictors with cholesterol level of cardiovascular mortahty and that serum total SA determinations could prove useful in Screening of populaUons at risk (18, 19) . SAis suggested to be involved in LDL metabolism as sialyladon of LDL may affect its receptor mediated cellular uptake, its catabolic rate and its susceptibility to oxidadon (20) . It is also known that serum SA is a relatively nonspecific indicator of inflammation, thus the elevation in SA level in cardiovascular diseases may be explained simply by increased levels of richly sialylated acute phase glycoproteins.
The role of infections in the pathogenesis of atherosclerosis and resulting cardiovascular diseases has been a major subject of debate for many years. Neopterin, which is a specific marker of macrophage activation and cellular immune Stimulation, is produced in substantial amounts upon Stimulation with the cytokine interferon-c and is commonly uscd for Screening subclinical viral infections (21) . Recently, atorvastatin was reported to directly inhibit Interferon-y-mediated neopterin formation in human monocytes (22) . Increased neopterin concentration was found in atherosclerosis of the coronary and carotid arteries, and in acute and chronic coronary dieases (6, 9, (23) (24) (25) . An association of serum neopterin levels with the presence of angiographically demonstrated lesions in patients with unstable angina was shown, and neopterin was reported as a marker of coronary disease activity (26) . Although the association between atherosclerosis and neopterin levels was reported more than a decade ago (27) , it is still not clear whethcr the measurement of neopterin concentrations in biological fluids of stable CAD patients contributes significantly to risk stratification and if it would prove to be beneficial to include these tests in the routine laboratory assessment of such patients.
In the present study, our objective was to test the inflammatory and immunological nature of atherosclerotic disease, by measuring the levels of various acute phase reactants and their association with serum and urine neopterin concentrations in 225 patients, angiographically grouped according to the severity and extent of CAD.
Materials and Methods
Patients and controls A group of 225 consecutive patients admitted to our university hospital for elective coronary angiography because of signs and symptoms of clinically stable coronary artery disease were included in the study. Current medications, cardiovascula:-risk factors and concomitant diseases were recorded N r.;-. f ihe patients and controls had concurrent iniectious, inflammatory or malignant disease. Patients with renal, hepatic, cardiac valvulär disease, previous cardiac surgery and those receiving statins as part of their treatment were also excluded. Based on the fact that this study required angiographic assessment of the coronary arteries, no true control group could be estah-lished because of the unacceptable health risk of coronary angiography in persons for whom this investigation is not medically warranted. Thus, out of the 225 patients who underwent coronary angiography , 63 patients with negative coronary angiograms were taken as the angiographic controls (group IV, 31 men, 32 womcn, mean age ± SD, 54.1 ±11.5 years). The remaining 162 patients were divided into three groups depending on the extent and severity of CAD observed during coronary angiography . Accordingly, group I comprised32 patients (20 men, 12 women, 59.7 ± 11.3 years) who were defined as the minor CAD group. Group II consisted of 34 patients (27 men, 7 women, mean age ± SD 60.0 ± 11.2 years) and was defmed as the moderate CAD group. The severe CAD group (group III) comprised 96 patients, 77 men, 19 women, 59.8 ± 9,31 years of age. The 225 patients who underwent CA (groups I-IV) were defined as group V. Apart from these patient groups, 40 healthy blood donors served as a control group (group VI, 27 men, 13 women. 55.9 ± 13.2 year.s) for the comparison of SA and neopterin concentrations within patients and healthy controls. All subjects were informed on the aim of the study and gave their written consent. The study was approved by the Ethics Committee of the Aegean University Medical Faculty. The demographic and clinical characteristics of the patients and controls are presented in Table 1 .
Coronan-angiography
In 225 patients with signs and Symptoms of clinically Stahle CAD, coronary angiography was performed using the Judkins technique for the evaluation of obstructive coronary lesions. Coronary artery stenosis were estimated visually by 2 independent observcrs who were blinded to the identities and clinical Information of the patients. The severity of CAD was delermined by the use of Gensini's coronary artery scoring method including the geometricaliy increasing severity of lesions, the cumulative effects of multiple obstructions, the significance of their locations, the modifying influence of the collaterals, and the size and quality of the distal vessels. Collatera! vessels were graded according to the Rentrop Classification system (28).
Specimen collection
On the day of coronary angiography . but before il was performed, after an overnight fast, blood was drawn by venipuncture into 10 ml piain tubes and into tubes containing 3.1 % trisodium citrate. Serum and plasma were isolated by centrifugation at 3000 g for .5 minutes and processed on the same day. Only cerulo plasmin, SA and neopterin determinations were performed in blood samples stored in aliquots at -80 oC until analysis.
Urine samples for the detennination of urinary neopterin were collected at the time of blood collection and frozen at -80°C.
Methods
Serum total and HDL-cholesterol, triglycerides and glucose concentrations, urinary Creatinine and the activities of cardiac enzymes aspartate aminotrans- ) . Serum ceruloplasmin concentration was measured by a method based on the oxidase activity of ceruloplasmin, in which the protein reacts with p-phenylenediamine to form a blue-colored product (29) . Serum total SA measurements were performed according to the method described by Sydow, based on the release of bound SA by heating with 5% perchloric acid and measuring the absorbance of the color developed after heating with Ehrlich's reagent, at 525 nm (30) . Serum and urine neopterin concentrations were measured by fluorometric detection on a Shimadzu LC lOA HPLC system (Shimadzu Corp., Kyoto, Japan) as previously described (31) . Urinary neopterin excretion was expressed as mmole/mole Creatinine.
Statistical
analysis Unicss otherwise indicated, data are presented as mean ± SD. Data within groups were compared by analysis of variance (ANOVA) and differences between groups by the t-test. A p value <0.05 was considered significant. In the case of group variables, the chi-square test was used. Correlations between dlfferent Parameters vsere tested by Pearson correlation analysis. The Statisucal Package for Social Sciences (SPSS Version 10,0, SPSS Inc,. Chicago, IL, USA) was used.
Results

Patients
As observed in (Tab. 1)., patients with angiographically verified CAD (groups LIII) demonstrated significant differences in gender distribution, smoking habits, presence of menopause, history of acutc myocardial infarction and Type II diabetes when compared with the angiographic control group (group IV) (p <0.05 for all comparisons). Male gender, smoking, menopause, acute myocardial infarction and Type II diabetes were more prominent in patients with angiographically established CAD. However. there was no significant difference with respect to age and frequency of hypertension between patients with CAD and the angiographic control group, Cardiac enz,ym.es Activities of serum CK, CK-MB, AST and LDH are presented in (Tab. 2). No significant difference was 
Serum lipids and glucose
Serum lipid and glucose data are presented in (Tab. 2). Lipid profile analyses revealed no significant difterences between patients with and without CAD and between groups with various extents of CAD. However, fasting blood glucose concentrations were significantly higher in patients with angiographically established CAD than in angiographic controls (p <0.01). When groups with CAD were compared with cach other, a trend towards higher fasting glucose concentrations was observed as the extent of CAD mcreased Table 2 . Namely, severe CAD group had significantly higher fasting glucose concentrations than the angiographic controls and the minor and moderate CAD groups (6.4 + 3-4 vs 5.1 ±2.1, p <0.01, 5.3 ± 1.9 and 5.3 ± 2.1 mmole/L, p <0.05 for both comparisons).
Hs-CRP
Hs-CRP levels were significantly higher in patients with CAD than in angiographic controls (group IV) (5.7 ± 3.5 vs 3.3 ± 1.8 mg/L, p <0.05). Patients with severe CAD exhibited significantly higher CRP levels than patients with moderate CAD (8.8 ± 4.3 vs 3.9 ± 3.1 mg/dl, p <0.05), and patients angiographically free of CAD (8.8 ± 4.3 vs 3.3 ± 1.8 mg/L, p <0.05) (Tab. 3).
Fibrinogen
Fibrinogen conccntrations were significantly mcreased in patients wilh established CAD as comparcd to patients angiographically free of CAD (3.34 ± I.IO vs 3.01 + 1.12 g/L, p <0.05). Patients with severe Table 3 . Concentrations of acute phase proteins, sialic acid and neopterin in all patienis wilh coronary artery disease (CAD) and controls. Data are presented as mean ± SD.
CAD had the highest fibrinogen concentrations, this value being significantly higher than the value m patients angiographically free of CAD (3.63 ± 1.23 vs 3.01 ± 1.12 g/L, p <0.05). Table 3 .
Ceruloplasmin
Ceruloplasmin concentrations tended to be higher in patients with CAD than in patients without angiographically established CAD, but the difference was not significant (462 ± 125 vs 441 ± 146 pmole/L, p >0.05). Comparisons among the groups wilh CAD did not manifest any significant differences between groups (Tab. 3).
Sialic acid (SA)
As Seen in Table 3 , serum total SA concenlraüons were significantly elevated in all the patients who underwent coronary angiography (group V) comparcd with healthy controls (group VI): 0.28 ± 0.07 vs 0.22 + 0.06 mmole/L, p <0.05). Patients who were angiographically free of CAD (group IV), cxhibited significantly higher SA concentrations than healthy controls (84.1 ± 19.1 vs68.2± 17.2 mmole/L, p <0.05). Serum SA concentrations in patients with moderate and severe CAD were also significantly higher than in controls (0.27 ± 0.06 and 0.29 ± 0.07 vs 0.22 ± 0.06 mmole/I., p <0.05). Serum SA concentrations did not differ between the four groups of patients undergoing coronary angiography.
Neopterin
Serum neopterin levels were significantly higher in patients undergoing coronary angiography (group V). compared with healthy controls (10.1 ± 5.46 vs 7.54 ± , revealed significantly higher neopterin levels in group IV (10.8 ± 6.6 vs 7.5 ± 2.6 nmole/1, p <0.05). Serum neopterin levels did not differ between the four patient groups undergoing coronary angiography. Neopterin values and differences between groups are presented in (Tab. 3). Similar to serum, urinary neopterin cxcretion tendcd to be higher than controls in all of the patients, but the difference did not reach the level ol' significance.
-
Stratification for smoking status did not exhibit any significant differences in serum and urine neopterin concentrations between the patient groups. However. as shown in (Fig. 1) , urinary neopterin cxcretion was higher in non-smokers within patients with severe CAD, patients with negative angiograms (group IV) and patients undergoing coronary angiography (group V), p <0.05 for all comparisons.
Stratification for gender revealed higher urinary neopterin concentrations in the female patients with minor, moderate, severe CAD and in patients with ne- Table 4 ., serum CRP exhibited significant positive correlations with fibrinogen, ceruloplasmin, SA, fasting glucose, LDH and a significant negative correlation with HDL cholesterol. Plasma fibrinogen was associated with cerulopjasmin, LDL-cholesterol, LDH and previous ML Sialic acid levels correlated significantly with fasting glucose, concurrent diabetes and age. Serum triglycerides were significantly associated with fasting glucose and previous history of MI (p <0.01 for all correlations). Significant negative correlations were ob.served between HDL-cholesterol and triglyceride concentrations (r = -0.33, p <0.01), previous history of MI (r = -0.13, p <0.05) and smoking (r = -0.17, p <0.01). As expected, serum total and HDL-cholesterol concentrations were strongly associated (r = 0 73. p<0.01).
Discussion
The concept of risk assessment and rcduction is crucial in lowering the incidence of acute coronary cvents in chronic stable CAD. Thus, novel serum markers that iacilitate non-invasive assessment of the cardiovascular system are under extensive investigation with the aim of determining their Utility in risk assessment. Atherosclerosis is defined as a chronic inflammatory disease in which an inflammatory response is considered as the key event.
A feature of most forms of inflammation is an increase in acute-phase proteins as a result of the Stimulation by cytokines, produced by activated macrophages and other cells. CRP is the most sensitive acutc-phase protein in humans and circulating levels of this protein precisely reflect the inflammatory activity. Elevated CRP levels were reported as predictors of coronary evcnts in patients with stable and unstable angina (2, 3) and in type 2 diabetics (32). In accordance with ihese reports, we measured significantly higher circulating CRP concentrations in patients with angiographically established CAD than in patients with negative angiograms. Moreover, the CRP levels were found to be significantly higher in patients with severe CAD, compared to those with moderate CAD or negative angiograms. CRP levels correlated with the cxtent and severity of CAD in all of our patients undergoing CA, indicating that CRP is not only a marker of disease presence, but also a quantitative indicator of disease. In our patients, CRP was also noted to be associated with fasting glucose concentrations This Observation supports the fmdings of other investigators who have reported CRP as a strong discriminator for CHD in type 2 diabetics (32). The negative correlation that we observed between CRP and HDL-C has been reported by others as wel! (3, 9) . HDL-C, a negative acute-phase reactant, consistently declines during the acute-phase response (33) . Recently, plasma CRP levels were shown to be strongiy associated with HDL-C concentrations in subjects with hyper/hypoalphalipoproteinemias (34) . According to the authors, in these subjects, HDL-C levels may account for plasma CRP, independent of other cardiovascular risk factors, We determined significant correlations between CRP and acute-phase proteins such as fibrinogen, ceruloplasmin and SA, a major component of acute-phase proteins. These findings are not surprising as sialylated glycoproteins are acute phase reactants which increase during the course of an inflammatory process. In our patients the association between CRP and LDH may indicate tissue injury in the presence of an inflammatory response.
Plasma fibrinogen concentrations showed a tendency to increase with the extent and severity of CAD; patients with severe CAD having higher fibrinogen concentrations than those with negative angiograms. Fibrinogen was also associated with two other inflammatory markers, namely CRP and ceruloplasmin, further supporting the inflammatory nature of the atherosclerotic process. We also found an association between fibrinogen and LDL-C concentrations, which is not surprising since dyslipidemia and coagulation disorders are well-established coronary risk markers. Fibrinogen was also associatcd with prcvious MI. In accordance, Reganon et al. reported higher plasma fibrinogen protem and function tliree years after AMI and pointed out to the very active role of procoagutant factors in recurrent ischemic events (4) . Besides, prcvious MI, fibrinogen concentrations were also associated with LDH activity, further supporting tissue damage related to the chronic inflammatory process and myocardial necrosis in patients with previous MI.
The contribution of elevated ccruloplasmin concentrations to the pathogenesis of cardiovascular disease has been investigated, however the results are conflicting (16) . It is not clear whether ceruloplasmin is an independent risk factor for CAD through oxidative modification of LDL-C or an elevated concentration of this protein is merely an indicator of inflammation According to some researchers, the latter is morc plausible (35) . In the present study, ceruloplasmin concentrations did not differ between patients with and without angiographically established CAD nor did the concentrations of this protein in any of the groups exhibit an association with the angiographic score. Our result.s Support the findings of Enbcrgs et al. (36) who could not demonstrate a correlation between ceruloplasmin concentrations and the angiographic extent of CAD.
Similar to ceruloplasmin, SA (SA) concentrations were also not different in patients undergoing CA, either with or without CAD. However in 40 healthy Controls, serum SA was significantly lower than the patients. Serum SA levels were significantly elevated in patients with moderate and severe CAD and in patients with negative angiograms, compared with healthy controls. However, correlation analysis did not reveal any association between serum SA levels and the angiographic score in any of the patients. SA was associated with some of the classical risk factors for CAD, namely age, fasting glucose and concurrent DM. Our findings support Salomone et al. (37) who reported that serum SA was not associated with the prcscncc or extent or severity of CAD in patients with stable angina. An elevated serum SA concentrations has been claimed to be a strong predictor of cardiovascular mortality (38, 39) . However, serum SA, being a relatively non-specific indicator of inflammation, its elevation in CAD may simply reflect increased concentrations of sialylated acute-phase proteins. The association that we observed between CRP and SA concentrations in all of our patients, supports this hypothesis. On the other hand, ours and previous findings suggest ihat, since it is not associated with the extent and severity of stable CAD, serum SA is not as sensitive as CRP and fibrinogen as a marker of inflammation in atherosclerotic vascular disease.
Macrophages cause LDL oxidation which is a key evcnl in the pathogenesis of atherosclerosis. Oxidized LDL is also immunogenic. Activation of the immune system contributes considerably to oxidant strcss (21) . Alihough the pysiological role of neopterin producüon by activaied monocytes/macrophages has not been tully elucidated, data imply a potential role of neopterin and its derivatives to modulate redox processes leading to LDL oxidation (40). Elevated levels of neopterin were reported in chronic stable CAD and even more pronounced elevations in acute coronary syndromes, supporting the vaiue of neopterin measurements as a marker of disease activation and adverse outcome (23, 25, 41). In our study, serum neopterin concentrations were significantly elevated in patients undergoing CA than in healthy controls. Urinary neopterin excretion was also higher than in controls, though the difference did not reach the significance ievel. Neopterin concentrations were similar between the different subgroups of CAD, suggesting ihat neopterin determinations do not contribute to the assessment of the presence and seventy of disease in clinically stable patients. Our results support the findings of Schumacher et al. who reported significant neopterin elevations in sera of patients with clinical signs ofCAD, compared to healthy blood donors (23). Recently, van Haelst et al. reported an association between serum neopterin and CRP concentrations in patients with non-Q-wavc MI (42). They have shown that neopterin is prediclive of adverse events in patients with non-Q-wave MI and that when combined with CRP, these two markers of inflammation were even stronger predictors for adverse events (death and rccurrent myocardial infarction). We have not observcd a correlation between neopterin and CRP concentrations in our patients. This may be due to ihe difference in the study populations between the two studies, theirs bemg patients with acute coronary Syndrome and Ours being clinically stable. We observed a positive association with neopterin levels and age, which is consistent with previous reports (21). Both serum and urmary neopterin concentrations exhibited a wcak positive association with LDH. This implies the co-existence of low-grade immune activation and consequent tissue damage in patients presenting with signs and symptoms of clinically stable CAD. This increase m neopterin concentrations was independent of the presence of angiographically verified CAD and the severity of disease. However, patients with clinically stable angina, including those with negative angiograms, had significantly higher serum neopterin concentrations than age and sex matched healthy controls. This implies that neopterin determinations in patients with stable angina do not prove to be usefui in discriminating between patients with negative and positive angiograms. Our data imply a low-gradc activation of the immune system that is independent of the angiographical findings in chronic stable angina. We observed higher urinary neopterin concentrations in non-smokers Ihan smokers withm patients with stable CAD which agrees well with findings in literature (43).
In conclusion, we did not find an association between serum and urinary neopterin concentrations and either the presence, extent or severity of coronary atherosclerosis in 225 patients with chronic stable angina. In these patients, serum hs-CRP and plasma fibrinogen levels proved to be more effective in the discrimination between patients with positive and negative angiograms and various degrees of CAD, thus pointing out to patients with higher cardiovascular risk. Our results, do not support the inclusion of serum and/or urinary neopterin in the risk assessment of patients with CAD.
